Miquelianin


CAS No. : 22688-79-5

(Synonyms: Quercetin 3-O-glucuronide; Quercetin 3-glucuronide)

22688-79-5
Price and Availability of CAS No. : 22688-79-5
Size Price Stock
5mg $99 In-stock
10mg $154 In-stock
25mg $330 In-stock
50mg $528 In-stock
100mg $858 In-stock
200 mg Get quote
500 mg Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via [email protected]

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-13930
M.Wt: 478.36
Formula: C21H18O13
Purity: >98 %
Solubility: DMSO : ≥ 30 mg/mL
Introduction of 22688-79-5 :

Miquelianin (Quercetin 3-O-glucuronide) is a metabolite of quercetin and a type of natural flavonoid. Miquelianin is also a CBR1 inhibitor. Miquelianin is permeable to the blood-brain barrier[1][2][3][4][5]. IC50 & Target:CBR1[6] In Vitro:Miquelianin shows an antioxidant effect in human plasma. At 50 μM, miquelianin suppresses the consumption of the three antioxidants lycopene, β-carotene and α-tocopherol significantly[1]. In vitro studies indicate that miquelianin is able to reach the central nervous system from the small intestine[2]. Miquelianin significantly reduces the generation of β-amyloid (Aβ) peptides by primary neuron cultures generated from the Tg2576 AD mouse model. It is also capable of interfering with the initial protein-protein interaction of Aβ1–40 and Aβ1–42 that is necessary for the formation of neurotoxic oligomeric Aβ species[3]. Treatment with 0.1 μM miquelianin suppresses ROS generation, cAMP and RAS activation, phosphorylation of ERK1/2 and the expression of HMOX1, MMP2, and MMP9 genes. Miquelianin suppresses invasion of MDA-MB-231 breast cancer cells and MMP-9 induction, and inhibits the binding of [3H]-NA to b2-AR. Miquelianin may function to suppress invasion of breast cancer cells by controlling b2-adrenergic signaling, and may be a dietary chemopreventive factor for stress-related breast cancer[4]. In Vivo:Miquelianin treatment, compared to vehicle-control treatment, significantly improves AD-type deficits in hippocampal formation basal synaptic transmission and long-term potentiation[3].

Your information is safe with us.